COMMUNIQUÉS West-GlobeNewswire

Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference
24/10/2025
FX-909, the first small molecule targeting PPARG to be tested in humans, showed monotherapy activity in advanced urothelial carcinoma with a favorable safety profile Strong safety, tolerability and efficacy data in a [...]
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors
24/10/2025
– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and clear clinical proof of concept, including confirmed responses in CRC, PDAC, and endometrial cancer – – First [...]
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
24/10/2025
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast [...]
Izotropic Corporation’s (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging System
24/10/2025
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within [...]
Incubator Stock Review Initiates Coverage on Vystar
24/10/2025
Worcester, MA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Vystar ® Corporation (OTCQB: VYST) Vystar announced today the Internet and Incubator Stock Review has initiated coverage. "We followed the team at Vystar over the past [...]
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
24/10/2025
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, [...]
Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
24/10/2025
Preliminary Results Yield 43% Overall Response Rates (via RECIST) in the Efficacy Population Data Demonstrate REM-422, the First-in-Class Small Molecule MYB mRNA Degrader, Reduces Expression of the MYB Oncogene [...]
Halda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC™ Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
24/10/2025
Anti-tumor activity was observed in heavily pretreated mCRPC patients across all dose cohorts; in 22 patients who completed at least 2 cycles of therapy, 59% achieved PSA50 response and 32% achieved PSA90 response All 5 [...]
Canatu grants license for commercial production of CNT pellicle membranes using CNT100 SEMI reactor
24/10/2025
VANTAA, Finland, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Canatu has granted a commercial production license for the first CNT100 SEMI reactor to Korean semiconductor company FINE SEMITECH CORPORATION (hereinafter “FST”). The [...]
Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference
24/10/2025
THE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
24/10/2025
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of neurodegenerative [...]
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
24/10/2025
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea [...]
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
24/10/2025
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignancies Disease stabilization observed in patients with tumors [...]
rYojbaba Expands Partnership with China Zhongqing International Holdings to Implement Free Labor Union Program for Japan’s Technical Intern Training and Specified Skilled Worker Programs
24/10/2025
FUKUOKA, Japan, Oct. 24, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”) , a Japanese labor consulting and health services company, announced a strategic partnership with China [...]
FibroBiologics to Present at Bio-Europe 2025
24/10/2025
HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor with a fully subcutaneous dose regimen
24/10/2025
Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD), 1 , 2 , 3 providing the simplicity of a fully subcutaneous dose regimen in [...]
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
24/10/2025
Achieves significant expansion of NeurAxis’ total addressable market Clearance now includes patients aged “8 years and older” Expanded age indication will utilize the upcoming January 1 st , 2026, Category I CPT code to [...]
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
24/10/2025
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
HealthLynked Launches New MedOfficeDirect Shopify Platform at DiscountOnlineMedicalSupplies.com with Improved Performance and Lower Prices
24/10/2025
NAPLES, Fla., Oct. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ), a leading provider of healthcare technology and patient engagement solutions, today announced the launch of its new [...]

Pages